Purple Biotech convenes a head, neck cancer SAB ahead of NT219 trial

Purple Biotech announced it convened a Scientific Advisory Board, SAB, focusing the discussions on NT219’s indication in recurrent/metastatic squamous cell carcinoma of the head and neck. “This scientific advisory board of head and neck cancer key opinion leaders, who are oncologists, researchers, and investigators, provided us their insights on the therapeutic landscape of R/M SCCHN treatment and invaluable guidance on clinical studies for NT219 in combination with cetuximab as a second/third line treatment and potentially in combination with a PD1 inhibitor as a first line treatment,” stated Purple Biotech CEO, Gil Efron. “Their recognition of the critical unmet need in recurrent and metastatic head and neck cancer provides further support and momentum to our development program. Now that we have determined the recommended Phase 2 dose, we are prepared to move to our next phase of development. We look forward to the head and neck cancer SAB’s continued guidance and support.” Head & Neck Cancer SAB Members Include: Douglas Adkins, Ezra Cohen, Antonio Jimeno, Lisa Licitra Francesca Linda, and Ari Rosenberg